[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Newamsterdam Pharma Company N.V. (NAMS)

Newamsterdam Pharma Company N.V. (NAMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,225,108
  • Shares Outstanding, K 119,537
  • Annual Sales, $ 22,500 K
  • Annual Income, $ -203,820 K
  • EBIT $ -244 M
  • EBITDA $ -244 M
  • 60-Month Beta 0.10
  • Price/Sales 141.67
  • Price/Cash Flow N/A
  • Price/Book 4.97

Options Overview Details

View History
  • Implied Volatility 78.59% (-4.80%)
  • Historical Volatility 52.44%
  • IV Percentile 54%
  • IV Rank 29.18%
  • IV High 137.17% on 09/15/25
  • IV Low 54.46% on 01/20/26
  • Expected Move (DTE 4) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.93
  • Today's Volume 58
  • Volume Avg (30-Day) 547
  • Put/Call OI Ratio 5.29
  • Today's Open Interest 30,605
  • Open Int (30-Day) 29,953
  • Expected Range 26.90 to 26.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.50
  • Number of Estimates 5
  • High Estimate $-0.35
  • Low Estimate $-0.62
  • Prior Year $-0.41
  • Growth Rate Est. (year over year) -21.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.74 +4.51%
on 08/05/26
32.63 -17.55%
on 07/22/26
-4.78 (-15.09%)
since 07/17/26
3-Month
25.74 +4.51%
on 08/05/26
37.37 -28.02%
on 07/07/26
-8.54 (-24.10%)
since 05/15/26
52-Week
23.05 +16.70%
on 09/15/25
42.21 -36.26%
on 05/11/26
+1.83 (+7.30%)
since 08/15/25

Most Recent Stories

More News
NewAmsterdam Pharma's Investor Day: Obicetrapib Data Could Redefine the Lipid-Lowering Narrative

Barchart Research What to Expect from NAMS Earnings NAMS Generated August 4, 2026 Current Price $27.55 EPS Estimate $$-0.48 Consensus Rating Strong Buy Average Move 7.04% NewAmsterdam Pharma's Investor...

NAMS : 26.90 (-0.30%)
An experimental Alzheimer's drug shows promise targeting a different brain protein, new study shows

An experimental drug might help slow early Alzheimer's disease in a markedly different way than current treatments — by lowering the brain's production of a protein called tau

DNLI : 24.35 (-0.20%)
IONS : 58.63 (+2.43%)
NAMS : 26.90 (-0.30%)
BIIB : 209.15 (-0.32%)
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends

NewAmsterdam Pharma (NASDAQ:NAMS) said it plans to conduct an interim analysis of its ongoing PREVAIL cardiovascular outcomes trial (CVOT) for obicetrapib in the fourth quarter of 2026, citing what executives...

NAMS : 26.90 (-0.30%)
Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

/CNW/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA)...

NAMS : 26.90 (-0.30%)
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg

– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies with high statistical...

NAMS : 26.90 (-0.30%)
NewAmsterdam Pharma Closes $452.6 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma closes a public offering, raising approximately $452.6 million for its LDL-C lowering therapies.Quiver AI SummaryNewAmsterdam Pharma Company N.V. has completed its underwritten public...

NAMS : 26.90 (-0.30%)
NewAmsterdam Pharma Prices $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma announces $416.5 million public offering of ordinary shares and pre-funded warrants to support cardiovascular treatments.Quiver AI SummaryNewAmsterdam Pharma Company N.V., a clinical...

NAMS : 26.90 (-0.30%)
NewAmsterdam Pharma Reports Positive Phase 3 Results for Obicetrapib in Lowering LDL-C and Reducing Cardiovascular Events

NewAmsterdam reports positive Phase 3 results for obicetrapib, showing significant LDL-C reduction and favorable safety profile compared to placebo.Quiver AI SummaryNewAmsterdam Pharma Company has reported...

NAMS : 26.90 (-0.30%)
NewAmsterdam Pharma Grants Inducement Share Options to New Non-Executive Hires

NewAmsterdam Pharma grants 79,000 share options to new hires as employment inducement under its 2024 Inducement Plan.Quiver AI SummaryNewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical firm...

NAMS : 26.90 (-0.30%)
NewAmsterdam Pharma Reports Significant Efficacy and Safety Results in Phase 3 BROOKLYN Trial of Obicetrapib for Heterozygous Familial Hypercholesterolemia

NewAmsterdam Pharma reports significant LDL-C and Lp(a) reductions with obicetrapib in Phase 3 trial, maintaining safety comparable to placebo.Quiver AI SummaryNewAmsterdam Pharma Company announced positive...

NAMS : 26.90 (-0.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

NewAmsterdam Pharma Holding B.V. is a late clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases. NewAmsterdam Pharma Holding B.V., formerly known as Frazier Lifesciences Acquisition Corporation, is based in MENLO PARK, Calif....

See More

Key Turning Points

3rd Resistance Point 28.24
2nd Resistance Point 27.81
1st Resistance Point 27.36
Last Price 26.90
1st Support Level 26.48
2nd Support Level 26.05
3rd Support Level 25.60

See More

52-Week High 42.21
Fibonacci 61.8% 34.89
Fibonacci 50% 32.63
Fibonacci 38.2% 30.37
Last Price 26.90
52-Week Low 23.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.